NCT04704661 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
10 trialsNCT07137416 2026-03-18
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting
NCT06663787 2025-11-28
HER2 CR
Nagoya City University
Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06504719 2025-09-15
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Hellenic Cooperative Oncology Group
Completed
NCT07151586 2025-09-03
ALTER
UNICANCER
Phase 2 Not yet recruiting
NCT03248492 2025-06-26
DESTINY-Breast01
Daiichi Sankyo
Phase 2 Terminated
NCT04420598 2025-06-24
DEBBRAH
MedSIR
Phase 2 Completed
NCT03523572 2025-01-27
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
Phase 1 Completed